NIH Reporter #5R01AI161085-05

NIAID Grant for Preclinical Antiviral Drug Development Targeting SARS-CoV-2

This opportunity is a research grant from the National Institute of Allergy and Infectious Diseases (NIAID), managed through Kansas State University, focused on antiviral drug development for COVID-19. - Government Buyer: - National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health - Grant administered via Kansas State University, Manhattan, Kansas - Products/Services Requested: - Research and development of small molecule inhibitors targeting the 3C-like protease of SARS-CoV-2 - Emphasis on preclinical candidate development for antiviral therapeutics - OEMs and Vendors: - No specific OEMs or commercial vendors are named in the notice - Notable Requirements: - Open to qualified research entities - Focused on infectious diseases research, specifically antiviral candidates for SARS-CoV-2 - No specific product part numbers, quantities, or commercial products listed - Estimated funding amount is $727,637 - No licensing or classification restrictions specified - Project classified under Infectious Diseases Research (PSC code 93.855)

Description

This is a research grant opportunity for developing antiviral therapeutics targeting the 3C-like protease of SARS-CoV-2, focusing on preclinical candidate development. The project is funded by the National Institute of Allergy and Infectious Diseases (NIAID) and managed through Kansas State University. The award amount is approximately $727,637, with a project duration from August 6, 2021, to January 31, 2027. The solicitation is open and active, with a standard response format and no specified license or classification requirements.

View original listing